In this study, we addressed the impact of chemotherapy in breast cancer patients with HER2-negative iLRR using a real-world clinical data collected from tertiary academic hospitals, and explored which patients would benefit from adjuvant chemotherapy following local treatment for iLRR. The gene discussed is ERBB2; the disease is breast carcinoma.